Podcast
“Sovereignty Means Being Able to Change Course” – A Conversation with Manfred Beckers
Digital sovereignty in finance: Manfred Beckers discusses cloud dependencies, DORA, exit strategies and maintaining the ability to adapt.
Compliance

01.12.2020|

CENTOGENE is committed to reducing patient’s suffering by accelerating and improving the accuracy of rare disease diagnosis. To that end, the Rostock-founded company has developed a unique genetic information database, CentoMD®. CentoMD® 5.8 currently contains over 430,000 analyzed cases as of August 2020 and is a powerful tool in making the rare disease diagnostic process easier, faster and more precise.
“We have a range of standard operating procedures that our medical professionals complete for data curation, and we were exploring the opportunities that artificial intelligence automation solutions could offer,” said Prof. Dr. Carsten Ullrich, Director of Artificial Intelligence at CENTOGENE.
Hans Jürgen Rieder, CEO at ACTICO added, “We are delighted to have enabled CENTOGENE to automate its data curation workflow using the ACTICO decision management system. We worked closely with our implementation partner S&D to ensure a rapid and smooth deployment, and we are very proud of the results.”
Dr. Martin Werber, Senior Technical Project Manager for AI at CENTOGENE, added, “We are now able to batch the processing of thousands of patient samples with this fully integrated solution and save up to one month of manual work for every release of a new version of CentoMD®. For patients, this represents a huge breakthrough. The time previously spent looking at cases of lower complexity can now be spent examining more difficult ones – meaning patients directly benefit.”
CENTOGENE joins hundreds of other businesses around the world that are using ACTICO’s decision management system to leverage the power of AI in automating complex and dynamic decision workflows intelligently.
More information about this success story.
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020.
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.
ACTICO is a leading international provider of software for intelligent automation and digital decisioning. Its scalable software combines rule-based technology and machine learning in a unique way and is totally audit-proof. It allows companies of all sizes to process huge amounts of data and make and automate AI-supported and rule-based decisions in real time. Through intelligent automation, ACTICO increases the business value of its customers by improving their operational decisions.
Today, its customers include leading companies in 25+ countries ranging from small/mid-size to Fortune 500 companies and has offices in Chicago and Singapore. Its head office is located in Immenstaad, Germany.
You may also be interested in:
Podcast
“Sovereignty Means Being Able to Change Course” – A Conversation with Manfred Beckers
Digital sovereignty in finance: Manfred Beckers discusses cloud dependencies, DORA, exit strategies and maintaining the ability to adapt.
Compliance
News
Chartis Research Again Names ACTICO a Category Leader for AML Transaction Monitoring 2026
ACTICO has again been named a Category Leader in the Chartis RiskTech Quadrant® for AML Transaction Monitoring Solutions 2026. The assessment recognizes ACTICO’s strengths in risk typology modeling, analytical modeling, model validation, workflow automation, and AI-powered compliance.
Anti-Money Laundering
Financial Institutions/FinTech, Insurance
Awards & Recognitions
News
ACTICO announces it has joined forces with Axe Finance, a global provider of credit and risk management software
ACTICO announces that it has joined forces with Axe Finance, a UK-based provider of credit and risk management software. The deal is supported by Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments.
Webinar On-Demand
Update on AML Requirements for Insurers: what you need to do now to be ready by July 2027.
AML update for insurers: What needs to be done by July 2027 regarding KYC, risk assessment and transaction monitoring? Including practical insights. Watch the webinar.
Anti-Money Laundering
Insurance
Newsletter
Regular News and Updates
Compliance
Asset Administration
Credit Risk
Decision Management
Resources
You are currently viewing a placeholder content from Hubspot Embedded Content. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Hubspot Meetings. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Wistia. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information